Advertisement
Advertisement
ALNY
Alnylam Pharmaceuticals, Inc.
294.40
USDSponsored
+8.13
+2.84%
May 19, 15:58 UTC -4
Open
ALNY Earnings Reports
Positive Surprise Ratio
ALNY beat 22 of 41 last estimates.
54%
Next Report
Date of Next Report
Jul 29, 2026
Estimate for Q2 26 (Revenue/ EPS)
$1.35B
/$1.56
Implied change from Q1 26 (Revenue/ EPS)
+15.69%
/+3.31%
Implied change from Q2 25 (Revenue/ EPS)
+74.53%
/-405.88%
Alnylam Pharmaceuticals, Inc. earnings per share and revenue
On Apr 30, 2026, ALNY reported earnings of 1.51 USD per share (EPS) for Q1 26, beating the estimate of 0.96 USD, resulting in a 56.51% surprise. Revenue reached 1.17 billion, compared to an expected 1.14 billion, with a 2.64% difference. The market reacted with a +2.76% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 16 analysts forecast an EPS of 1.56 USD, with revenue projected to reach 1.35 billion USD, implying an increase of 3.31% EPS, and increase of 15.69% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
Satellos Bioscience Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.61
Actual
-$0.53
Surprise
+13.58%
Rani Therapeutics Holdings, Inc. Class A Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.04
Surprise
+12.85%
aTyr Pharma, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.14
Actual
-$0.11
Surprise
+21.60%
Citius Oncology, Inc. Common Stock
Report Date
May 15, 2026 For Q2 26
Estimate
-$0.01
Actual
-$1.43
Surprise
-13919.61%
Instil Bio, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.59
Actual
-$0.62
Surprise
-4.04%
Annovis Bio, Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.40
Actual
-$0.63
Surprise
-56.37%
CervoMed Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.79
Actual
-$0.86
Surprise
-8.09%
Lantern Pharma Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+18.30%
Cocrystal Pharma, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.17
Surprise
-11.11%
FAQ
What were Alnylam Pharmaceuticals, Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Alnylam Pharmaceuticals, Inc. reported EPS of $1.51, beating estimates by 56.51%, and revenue of $1.17B, 2.64% above expectations.
How did the market react to Alnylam Pharmaceuticals, Inc.'s Q1 2026 earnings?
The stock price moved up 2.76%, changed from $301.19 before the earnings release to $309.49 the day after.
When is Alnylam Pharmaceuticals, Inc. expected to report next?
The next earning report is scheduled for Jul 29, 2026.
What are the forecasts for Alnylam Pharmaceuticals, Inc.'s next earnings report?
Based on 16
analysts, Alnylam Pharmaceuticals, Inc. is expected to report EPS of $1.56 and revenue of $1.35B for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement